Literature DB >> 26512454

Lenalidomide: deciphering mechanisms of action in myeloma, myelodysplastic syndrome and beyond.

Andrew A Guirguis1, Benjamin L Ebert2.   

Abstract

Lenalidomide and its related 'analogues' modulate the substrate specificity of the CRL4(CRBN) E3 ubiquitin ligase complex. Polyubiquitination and subsequent proteasomal degradation of IKZF1 and IKZF3 in multiple myeloma and CK1α in del(5q) MDS has recently been linked to therapeutic efficacy of this class of compounds. Harnessing ubiquitin ligase substrate specificity, may in time facilitate the degradation of other 'undruggable' proteins and allow for separation of detrimental side effects of IMiD compounds from those associated with therapeutic efficacy.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26512454     DOI： 10.1016/j.ceb.2015.10.004

Source DB:  PubMed          Journal:  Curr Opin Cell Biol        ISSN： 0955-0674            Impact factor:   8.382


  9 in total

1.  IMiD compounds affect CD34+ cell fate and maturation via CRBN-induced IKZF1 degradation.

Authors:  Shirong Li; Jing Fu; Hui Wang; Huihui Ma; Xiaoming Xu; Yong-Guang Yang; Shixian Deng; Markus Y Mapara; Suzanne Lentzsch
Journal:  Blood Adv       Date:  2018-03-13

2.  IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia.

Authors:  Brandon J Aubrey; Jevon A Cutler; Wallace Bourgeois; Katherine A Donovan; Shengqing Gu; Charlie Hatton; Sarah Perlee; Florian Perner; Homa Rahnamoun; Alexandra C P Theall; Jill A Henrich; Qian Zhu; Radosław P Nowak; Young Joon Kim; Salma Parvin; Anjali Cremer; Sarah Naomi Olsen; Nicholas A Eleuteri; Yana Pikman; Gerard M McGeehan; Kimberly Stegmaier; Anthony Letai; Eric S Fischer; X Shirley Liu; Scott A Armstrong
Journal:  Nat Cancer       Date:  2022-05-09

3.  Thalidomide and lenalidomide for recurrent ovarian cancer: A systematic review of the literature.

Authors:  Clemens B Tempfer; Beate Schultheis; Ziad Hilal; Askin Dogan; Günther A Rezniczek
Journal:  Oncol Lett       Date:  2017-07-15       Impact factor: 2.967

4.  pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4CRBN ubiquitin ligase.

Authors:  Jian An; Charles M Ponthier; Ragna Sack; Jan Seebacher; Michael B Stadler; Katherine A Donovan; Eric S Fischer
Journal:  Nat Commun       Date:  2017-05-22       Impact factor: 14.919

Review 5.  Specific targeting of the deubiquitinase and E3 ligase families with engineered ubiquitin variants.

Authors:  Maryna Gorelik; Sachdev S Sidhu
Journal:  Bioeng Transl Med       Date:  2016-11-14

Review 6.  Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide.

Authors:  Nianhang Chen; Simon Zhou; Maria Palmisano
Journal:  Clin Pharmacokinet       Date:  2017-02       Impact factor: 6.447

7.  Biological evaluation of both enantiomers of fluoro-thalidomide using human myeloma cell line H929 and others.

Authors:  Etsuko Tokunaga; Hidehiko Akiyama; Vadim A Soloshonok; Yuki Inoue; Hideaki Hara; Norio Shibata
Journal:  PLoS One       Date:  2017-08-01       Impact factor: 3.240

8.  PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs.

Authors:  Laurie Herviou; Alboukadel Kassambara; Stéphanie Boireau; Nicolas Robert; Guilhem Requirand; Carsten Müller-Tidow; Laure Vincent; Anja Seckinger; Hartmut Goldschmidt; Guillaume Cartron; Dirk Hose; Giacomo Cavalli; Jerome Moreaux
Journal:  Clin Epigenetics       Date:  2018-10-03       Impact factor: 6.551

Review 9.  Role of Polycomb Complexes in Normal and Malignant Plasma Cells.

Authors:  Emmanuel Varlet; Sara Ovejero; Anne-Marie Martinez; Giacomo Cavalli; Jerome Moreaux
Journal:  Int J Mol Sci       Date:  2020-10-28       Impact factor: 5.923
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.